Enterprise Value
709.7M
Cash
413.9M
Avg Qtr Burn
-24.07M
Short % of Float
27.80%
Insider Ownership
3.13%
Institutional Own.
81.30%
Qtr Updated
06/30/23
Drug Pipeline
Powered by

Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
Drug & Indication | Stage & Event | Catalyst Date |
---|---|---|
OCALIVA® (obeticholic acid) Details Primary biliary cholangitis, Infectious disease, COVID-19, Liver disease | Approved Quarterly sales | |
Ocaliva + Bezafibrate Details Primary biliary cholangitis, Liver disease | Phase 2 Update | |
INT-787 Details Liver disease, Alcoholic hepatitis | Phase 2a Update | |
Ocaliva Details Primary sclerosing cholangitis, Liver disease | Failed Discontinued | |
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued | |
Ocaliva Details Non-alcoholic steatohepatitis , Liver disease | Failed Discontinued |